INOVIO Pharmaceuticals

INOVIO Reports Inducement Grant Under Inducement Plan

by

PLYMOUTH MEETING, Pa., Feb. 2, 2024 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the “Inducement Plan”). The Compensation … Read more

INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

by

PLYMOUTH MEETING, Pa., May 23, 2023 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company’s product candidate for the treatment of Recurrent Respiratory … Read more